Our current research reveals a previously unrecognized mechanism by which estrogen affects CCL2 regulation in ER+ breast cancer and identifies CCL2-CCR2 axis as a new feasible target for resistance to endocrinotherapy. Here, CCR2 is linked to breast cancer.